Reports Q4 revenue $5.89B, consensus $5.91B. “Our resilient business model and commitment to commercial and operational execution enabled us to deliver 3.9% organic growth in New BD along with substantial adjusted margin and earnings growth in fiscal 2025,” said Tom Polen, chairman, CEO and president of BD. “We remain on track to complete the combination of BD’s Biosciences and Diagnostic Solutions business with Waters Corporation around the end of the first quarter of calendar year 2026. New BD will be a leading Med Tech company making a profound impact on health care and patients worldwide. By focusing on growth in attractive markets and executing BD Excellence, we are driving stronger margins, earnings expansion and long-term value.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Notable companies reporting before tomorrow’s open
- Becton gets full enrollment in iliac artery patient cohort in AGILITY study
- BDX Upcoming Earnings Report: What to Expect?
- Becton Dickinson receives FDA clearance, CE mark for enteric bacterial panels
- BD’s New Vascular Access Study: What Investors Need to Know